Welcome to our dedicated page for Merus N.V. Common Shares news (Ticker: MRUS), a resource for investors and traders seeking the latest updates and insights on Merus N.V. Common Shares stock.
Merus N.V. (Nasdaq: MRUS) is a clinical-stage immuno-oncology company focused on creating innovative therapies to treat and potentially cure cancer. At the heart of Merus' approach is its proprietary Biclonics® and Triclonics® technology platforms, which generate full-length human bispecific and trispecific antibodies. These advanced therapeutics are designed to engage the immune system to kill tumor cells and inhibit tumor cell growth pathways simultaneously.
Core Business
Merus' core business revolves around the discovery and development of bispecific antibody therapeutics. Their flagship technology, Biclonics®, can attack tumors in multiple ways, making them highly effective against various cancer types. The company’s portfolio includes several promising candidates, such as MCLA-128, which targets HER2 and HER3 receptors in gastric and breast cancers; MCLA-117, targeting AML; MCLA-158 (petosemtamab), focused on head and neck squamous cell carcinoma; and MCLA-145, developed for solid tumors.
Latest Achievements and News
As of May 2024, Merus has received the FDA's Breakthrough Therapy Designation (BTD) for petosemtamab in treating patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) that has progressed after treatment with platinum-based chemotherapy and PD-1/PD-L1 antibodies. This significant milestone is based on the promising data from the ongoing phase 1/2 trial of petosemtamab as a monotherapy, showing substantial improvement in clinically significant endpoints. Furthermore, Merus has announced plans to initiate a phase 3 trial in mid-2024 to evaluate the combination of petosemtamab and pembrolizumab in previously untreated patients.
Additionally, Merus revealed the acceptance of abstracts for MCLA-145 and MCLA-129 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. These presentations highlighted the clinical activity of MCLA-145 in advanced solid tumors and the efficacy of MCLA-129 in non-small cell lung cancer (NSCLC).
Financial Condition and Partnerships
Merus has a solid financial foundation, bolstered by strategic partnerships and collaborations. Notably, Merus collaborates with Betta Pharmaceuticals to develop MCLA-129 in China while retaining global rights outside China. The company’s financial strategy includes advancing its clinical development programs and supporting preclinical research and technology development through successful capital raises.
About Merus N.V.
Merus N.V. is dedicated to the development of multispecific antibody therapeutics, referred to as Multiclonics®. These therapeutics have been observed in preclinical and clinical studies to exhibit the same features as conventional human monoclonal antibodies, including long half-life and low immunogenicity. For more information, visit Merus’ official website, Twitter, and LinkedIn.
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced that its CEO, Bill Lundberg, M.D., will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on April 13 from 10:15-10:55 a.m. ET. The event will be accessible via a live webcast on the Company's investor page, with an archived version available afterward. Merus specializes in developing innovative multispecific antibodies, including its unique Biclonics® and Triclonics®, which show promise in clinical studies.
Rallybio Corporation announces significant changes to its Board of Directors. Christine Nash and Hui Liu have been appointed as new members, bringing extensive experience in rare diseases and business development, respectively. Tim Shannon, M.D. will resign from the Board, effective at the 2022 Annual Meeting of Shareholders. The company aims to leverage the expertise of new board members to advance its product portfolio for rare diseases.
Merus N.V. (MRUS) has announced the upcoming presentation of a poster discussing the mechanism and effectiveness of its drug MCLA-129 at the AACR Annual Meeting 2022 on April 10. MCLA-129 targets EGFR and c-MET, critical in treating non-small cell lung cancer (NSCLC). Currently, MCLA-129 is in a phase 1/2 clinical trial aimed at assessing safety, tolerability, and clinical activity in patients with advanced tumors. Merus has a collaboration with Betta Pharmaceuticals for its development in China while retaining global rights outside the region.
Merus N.V. (Nasdaq: MRUS) reported financial results for 2021, revealing a net loss of $66.8 million.
Collaboration revenue increased to $49.1 million, up from $29.9 million in 2020, driven by substantial contributions from Lilly and Incyte. Research and development expenses rose to $98.2 million, reflecting higher costs related to zenocutuzumab (Zeno) and MCLA-129. The company ended the year with cash, cash equivalents, and marketable securities of $430.7 million, projected to sustain operations beyond 2024. Clinical updates for Zeno, petosemtamab, and MCLA-129 are expected in 2022.
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced that CEO Bill Lundberg will participate in several upcoming investor conferences. These include the Guggenheim Healthcare Talks/2022 Oncology Conference on February 10, the Citi 2022 Virtual Immuno-Oncology Summit on February 16, and the 11th Annual SVB Leerink Global Healthcare Conference on February 17. Webcasts of these events will be available on the Company's Investors page, with archived presentations accessible for a limited time.
Merus N.V. (Nasdaq: MRUS) has appointed Shannon Campbell as the Executive Vice President & Chief Commercial Officer, effective February. With over 25 years of experience in pharmaceuticals, Campbell aims to enhance Merus's commercial strategy for its lead candidate, zenocutuzumab, and its pipeline of innovative antibodies. Additionally, Merus has regained global rights to MCLA-145 following Incyte's decision to opt-out of ex-U.S. development, providing an opportunity to advance this candidate in solid tumors.
Merus N.V. (Nasdaq: MRUS) has presented positive clinical data for zenocutuzumab (Zeno) in combination with trastuzumab and vinorelbine, targeting HER2+ metastatic breast cancer (MBC) at the San Antonio Breast Cancer Symposium. The triplet combination met its primary endpoint with a clinical benefit rate (CBR) of 49% after 24 weeks. This combination demonstrates meaningful activity in patients who have undergone extensive prior therapies. Despite positive results, Merus does not plan to advance to a phase 3 trial for MBC without a partner but will focus on other indications.
Merus N.V. (Nasdaq: MRUS) presented clinical data on MCLA-145 at the virtual ESMO Immuno-Oncology Congress 2021. The phase 1 trial, involving 34 patients with solid tumors, showed preliminary evidence of antitumor activity, especially at doses ≥25 mg biweekly. Patients were treated at eight dose levels with a median age of 60.5 years. While treatment-related adverse events occurred in 67.6% of patients, robust T-cell activation was recorded. The trial aims to refine the maximum tolerated dose and evaluate efficacy in PD-L1+ tumors.
Merus N.V. (MRUS) announced interim data from the phase 1/2 trial of its bispecific antibody MCLA-145, targeting CD137 and PD-L1 in solid tumors, as of July 14, 2021. This data will be presented at the ESMO Immuno-Oncology Congress 2021 from December 8-11, 2021. The ongoing trial includes a dose escalation phase followed by planned expansion, marking MCLA-145 as a key candidate co-developed with Incyte. Merus retains commercialization rights in the U.S. and aims to leverage its innovative Bispecific platform for enhanced cancer treatment.
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, has announced that CEO Bill Lundberg, M.D., will participate in a fireside chat at the Jefferies London Healthcare Conference. This virtual event is scheduled for November 18, 2021, and the prerecorded session will be available on the Company's investor webpage at 8:00 am GMT/3:00 am ET. Merus is known for developing innovative multispecific antibody therapeutics, Biclonics and Triclonics, which show potential advantages similar to conventional human monoclonal antibodies.
FAQ
What is the current stock price of Merus N.V. Common Shares (MRUS)?
What is the market cap of Merus N.V. Common Shares (MRUS)?
What is the core business of Merus N.V.?
What are some of Merus' key product candidates?
What significant recent achievement has Merus reported?
What are Biclonics®?
What is the status of MCLA-145 and MCLA-129?
What are Multiclonics®?
Who are Merus' key partners?
What are the financial strategies of Merus?
What is the purpose of the latest capital raise by Merus?
Where can I find more information about Merus N.V.?
